References:
1. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone associated
proarrhythmic effect. A review with special reference to torsade de
pointes tachycardia. Ann Intern Med 1994;121:529-35.
2. Connoly SJ. Evidence based analysis of amiodarone efficacy and
safety. Circulation. 1999;100:2025-2034.
3. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W.
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de
Pointes in Germany. Europace. 2014;16(January(1)):101-108.
4. Kirchhof P, Benussi S, Kotecha D, et al. ESC
Guidelines for the management of atrial fibrillation developed in
collaboration with EACTS. Eur Heart J. 2016;37(October (38)):2893-2962.
5. Shenthar J, Rachaiah JM, Pillai V et al. Incidence of drug-induced
torsades de pointes with intravenous amiodarone. Indian Heart J. 2017
Nov-Dec;69(6):707-713.
6. Psirropoulos D, Lefkos N, Boudonas G et al. Incidence of and
predicting factors for torsades de pointes during intravenous
administration of amiodarone. Heart Drug.2001;1(4):186-191.
7. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic Mechanism of
the Long QT Interval Syndromes and Torsade de Pointes. Ann Intern Med.
1995;122:701-14.
8. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects
of amiodarone on atrioventricular nodal function and slow-channel action
potentials: evidence for calcium channel blocking activity. Circulation.
1987;76:442-9.
9. Schrickel JW, Schwab JO, Yang A, et al. Pro-arrhythmic effects of
amiodarone and concominant rate-control medication. Europace.2006;8(May
(6)):403-407.
10. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic
agents: sex-based differences and other issues. Am J Cardiol.
2003;91:D39-44.
Figure legends:
Fig.1 ECG on admission revealing rapid atrial fibrillation.
Fig.2 ECG showing episodes of TdP and markedly prolonged QT interval.
Fig.3 ECG with temporal pacemaker at 75 bpm.